These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 33581653)

  • 1. Danthron ameliorates obesity and MAFLD through activating the interplay between PPARα/RXRα heterodimer and adiponectin receptor 2.
    Ma C; Wang Z; Xia R; Wei L; Zhang C; Zhang J; Zhao L; Wu H; Kang L; Yang S
    Biomed Pharmacother; 2021 May; 137():111344. PubMed ID: 33581653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adiponectin homolog novel osmotin protects obesity/diabetes-induced NAFLD by upregulating AdipoRs/PPARα signaling in ob/ob and db/db transgenic mouse models.
    Ahmad A; Ali T; Kim MW; Khan A; Jo MH; Rehman SU; Khan MS; Abid NB; Khan M; Ullah R; Jo MG; Kim MO
    Metabolism; 2019 Jan; 90():31-43. PubMed ID: 30473057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel small molecule AdipoR2 agonist ameliorates experimental hepatic steatosis in hamsters and mice.
    Zhao Y; Sun N; Song X; Zhu J; Wang T; Wang Z; Yu Y; Ren J; Chen H; Zhan T; Tian J; Ma C; Huang J; Wang J; Zhang Y; Yang B
    Free Radic Biol Med; 2023 Jul; 203():69-85. PubMed ID: 37044149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saikosaponin D attenuates metabolic associated fatty liver disease by coordinately tuning PPARα and INSIG/SREBP1c pathway.
    Gu Y; Duan S; Ding M; Zheng Q; Fan G; Li X; Li Y; Liu C; Sun R; Liu R
    Phytomedicine; 2022 Aug; 103():154219. PubMed ID: 35691075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wogonin mitigates nonalcoholic fatty liver disease via enhancing PPARα/AdipoR2, in vivo and in vitro.
    Chen J; Liu J; Wang Y; Hu X; Zhou F; Hu Y; Yuan Y; Xu Y
    Biomed Pharmacother; 2017 Jul; 91():621-631. PubMed ID: 28486193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. α-Lactalbumin Peptide Asp-Gln-Trp Ameliorates Hepatic Steatosis and Oxidative Stress in Free Fatty Acids-Treated HepG2 Cells and High-Fat Diet-Induced NAFLD Mice by Activating the PPARα Pathway.
    Chen H; Ma Y; Qi X; Tian J; Ma Y; Niu T
    Mol Nutr Food Res; 2023 Aug; 67(16):e2200499. PubMed ID: 37354055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lycopus lucidus Turcz. ex Benth. Attenuates free fatty acid-induced steatosis in HepG2 cells and non-alcoholic fatty liver disease in high-fat diet-induced obese mice.
    Lee MR; Yang HJ; Park KI; Ma JY
    Phytomedicine; 2019 Mar; 55():14-22. PubMed ID: 30668424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel fatty acid mimetic with pan-PPAR partial agonist activity inhibits diet-induced obesity and metabolic dysfunction-associated steatotic liver disease.
    Sahin C; Melanson JR; Le Billan F; Magomedova L; Ferreira TAM; Oliveira AS; Pollock-Tahari E; Saikali MF; Cash SB; Woo M; Romeiro LAS; Cummins CL
    Mol Metab; 2024 Jul; 85():101958. PubMed ID: 38763495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alisol A 24-Acetate Prevents Hepatic Steatosis and Metabolic Disorders in HepG2 Cells.
    Zeng L; Tang W; Yin J; Feng L; Li Y; Yao X; Zhou B
    Cell Physiol Biochem; 2016; 40(3-4):453-464. PubMed ID: 27889747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochanin A improves hepatic steatosis and insulin resistance by regulating the hepatic lipid and glucose metabolic pathways in diet-induced obese mice.
    Park HS; Hur HJ; Kim SH; Park SJ; Hong MJ; Sung MJ; Kwon DY; Kim MS
    Mol Nutr Food Res; 2016 Sep; 60(9):1944-55. PubMed ID: 27145114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice.
    Goto T; Teraminami A; Lee JY; Ohyama K; Funakoshi K; Kim YI; Hirai S; Uemura T; Yu R; Takahashi N; Kawada T
    J Nutr Biochem; 2012 Jul; 23(7):768-76. PubMed ID: 21889885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asperuloside activates hepatic NRF2 signaling to stimulate mitochondrial metabolism and restore lipid homeostasis in high fat diet-induced MAFLD.
    He C; Zhang Q; Zhu R; Tse G; Wong WT
    Eur J Pharmacol; 2024 Nov; 983():177003. PubMed ID: 39278309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The HIF-2α/PPARα pathway is essential for liraglutide-alleviated, lipid-induced hepatic steatosis.
    Wang H; Wang L; Li Y; Luo S; Ye J; Lu Z; Li X; Lu H
    Biomed Pharmacother; 2021 Aug; 140():111778. PubMed ID: 34062416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-34a regulates mitochondrial content and fat ectopic deposition induced by resistin through the AMPK/PPARα pathway in HepG2 cells.
    Wen F; An C; Wu X; Yang Y; Xu J; Liu Y; Wang C; Nie L; Fang H; Yang Z
    Int J Biochem Cell Biol; 2018 Jan; 94():133-145. PubMed ID: 29197627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oleuropein mitigates non-alcoholic fatty liver disease (NAFLD) and modulates liver metabolites in high-fat diet-induced obese mice via activating PPARα.
    Zhou W; Du Z
    J Sci Food Agric; 2024 Nov; 104(14):8634-8645. PubMed ID: 38952322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of diet-induced hepatic steatosis by peripheral CB1 receptor blockade in mice is p53/miRNA-22/SIRT1/PPARα dependent.
    Azar S; Udi S; Drori A; Hadar R; Nemirovski A; Vemuri KV; Miller M; Sherill-Rofe D; Arad Y; Gur-Wahnon D; Li X; Makriyannis A; Ben-Zvi D; Tabach Y; Ben-Dov IZ; Tam J
    Mol Metab; 2020 Dec; 42():101087. PubMed ID: 32987186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canagliflozin ameliorates obesity by improving mitochondrial function and fatty acid oxidation via PPARα in vivo and in vitro.
    Wei D; Liao L; Wang H; Zhang W; Wang T; Xu Z
    Life Sci; 2020 Apr; 247():117414. PubMed ID: 32035928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis.
    Xu H; Zhao Q; Song N; Yan Z; Lin R; Wu S; Jiang L; Hong S; Xie J; Zhou H; Wang R; Jiang X
    Nat Commun; 2020 Nov; 11(1):5807. PubMed ID: 33199780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.